[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

[Eli Lilly and Company](/topic/eli-lilly)

### Sentiment: XX%
![Sentiment Line Chart](https://lunarcrush.com/gi/w:600/t:eli-lilly/c:line/m:sentiment/iv:1d.svg)  
[Sentiment 24-Hour Time-Series Raw Data](/topic/eli-lilly/time-series/sentiment.tsv)  
**Current Value**: XX%  
**Daily Average**: XX%  
**1 Week**: XX% +1%  
**1 Month**: XX% -X%  
**6 Months**: XX% +2%  
**1 Year**: XX% -X%  
**1-Year High**: XX% on 2025-07-08  
**1-Year Low**: XX% on 2025-06-24  

**Most Supportive Themes**
- **Eli Lilly's Investment in India:** (35%) Eli Lilly's commitment to invest over $X billion in India to expand manufacturing and supply chains, particularly for Mounjaro, is viewed positively.
- **Positive Sentiment on Weight Loss Drugs:** (30%) The success of Eli Lilly's weight loss drugs, Zepbound and Mounjaro, and the potential of their oral pill, orforglipron, generate positive sentiment.
- **FDA Official Joins Eli Lilly:** (15%) The hiring of a former FDA official by Eli Lilly is seen as a positive move, potentially strengthening the company's research and development.
  
**Most Critical Themes**
- **Price Increase Concerns:** (10%)  The announced price increase for Mounjaro in the UK has sparked concerns about accessibility and affordability.
- **Competition and Market Dynamics:** (10%)  Competition from Novo Nordisk and other players in the weight loss market, along with potential regulatory and pricing pressures, pose risks.
  
Network engagement breakdown:  
| Network | Positive | %   | Neutral | %   | Negative | %  |
| ------- | -------- | -   | ------- | -   | -------- | -  |
| X       | XXXXXXX  | XX% | XXXXXXX | XX% | XXXXXX   | X% |
| TikTok  | XXXXX    | X%  | XXXXXX  | X%  | XXXXX    | X% |
| YouTube | XXXXX    | X%  | XXXXX   | X%  | XXXXXX   | X% |
| Reddit  | XX       | X%  | XXX     | X%  | XX       | X% |
| News    | XXXXXX   | X%  | XXX     | X%  | XXX      | X% |
|         |          |     |         |     |          |    |
| Total   | XXXXXXX  | XX% | XXXXXXX | XX% | XXXXXX   | X% |